RYR2 and Duchenne muscular dystrophy: Moreover, Kendall et al. reported that dantrolene, a RYR-targeting compound, which is currently used as a chronic treatment for malignant hyperthermia and muscle spasticity, synergizes with antisense-mediated exon skipping therapies in mdx mice and in inducible directly reprogrammable myotubes (iDRMs) derived from fibroblasts of patients with DMD [63].